The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials

被引：5
|
作者：
Salam, AM
Al-Mousa, EN
机构：
[1] Hamad Med Corp, Dept Cardiol & Cardiovasc Surg, Doha, Qatar
[2] Jordan Univ Hosp, Amman, Jordan
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2004年 / 5卷 / 06期
关键词：
anticoagulation; atrial fibrillation; cerebrovascular disease; clinical trials; coronary artery disease; direct thrombin inhibitors; heparin; melagatran; stroke prevention; thrombosis; venous thromboembolism; warfarin; ximelagatran;
D O I：
10.1517/14656566.5.6.1423
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Ximelagatran (Exanta(TM), AstraZeneca) is a novel oral direct thrombin inhibitor that inhibits the final step in the coagulation process - namely, the conversion of fibrinogen to insoluble fibrin by thrombin. Recently completed large clinical trials have evaluated the efficacy and safety of ximelagatran compared to standard anticoagulation therapy with warfarin and heparins in several thrombotic disorders including the treatment and prevention of venous thromboembolism following major orthopaedic surgery; stroke prevention in atrial fibrillation; and after acute myocardial infarction. This article reviews these recent clinical trials and explores the therapeutic potential of ximelagatran to become the oral anticoagulant of first choice in medicine.
引用
收藏
页码：1423 / 1430
页数：8
相关论文
共 50 条
  • [1] β-blockers in heart failure:: recently completed and ongoing clinical trials
    McAreavey, D
    Exner, DV
    Curtin, EL
    Domanski, MJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (02) : 415 - 428
  • [2] The therapeutic potential of resveratrol: a review of clinical trials
    Adi Y. Berman
    Rachel A. Motechin
    Maia Y. Wiesenfeld
    Marina K. Holz
    npj Precision Oncology, 1
  • [3] The therapeutic potential of resveratrol: a review of clinical trials
    Berman, Adi Y.
    Motechin, Rachel A.
    Wiesenfeld, Maia Y.
    Holz, Marina K.
    NPJ PRECISION ONCOLOGY, 2017, 1
  • [4] The therapeutic potential of curcumin: A review of clinical trials
    Salehi, Bahare
    Stojanovic-Radic, Zorica
    Matejic, Jelena
    Sharifi-Rad, Mehdi
    Kumar, Nanjangud V. Anil
    Martins, Natalia
    Sharifi-Rad, Javad
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 163 : 527 - 545
  • [5] The Therapeutic Potential of Naringenin: A Review of Clinical Trials
    Salehi, Bahare
    Fokou, Patrick Valere Tsouh
    Sharifi-Rad, Mehdi
    Zucca, Paolo
    Pezzani, Raffaele
    Martins, Natalia
    Sharifi-Rad, Javad
    PHARMACEUTICALS, 2019, 12 (01)
  • [6] Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials
    Kumarasamy, Ranil Vikraman
    Natarajan, Prabhu Manickam
    Umapathy, Vidhya Rekha
    Roy, Jeane Rebecca
    Mironescu, Monica
    Palanisamy, Chella Perumal
    FRONTIERS IN NANOTECHNOLOGY, 2024, 6
  • [7] Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials
    Hakami, Alqassem Y.
    Alshehri, Fahad S.
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [8] Autophagy: Can it become a potential therapeutic target? (Review)
    Bao, Xiao Hong
    Naomoto, Yoshio
    Hao, Hui Fang
    Watanabe, Nobuyuki
    Sakurama, Kazufumi
    Noma, Kazuhiro
    Motoki, Takayuki
    Tomono, Yasuko
    Fukazawa, Takuya
    Shirakawa, Yasuhiro
    Yamatsuji, Tomoki
    Matsuoka, Junji
    Takaoka, Munenori
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 25 (04) : 493 - 503
  • [9] Cannabinoids in medicine: A review of their therapeutic potential
    Amar, MB
    JOURNAL OF ETHNOPHARMACOLOGY, 2006, 105 (1-2) : 1 - 25
  • [10] Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs
    Goyal, Namita A.
    Mozaffar, Tahseen
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (11) : 1541 - 1551
12345